Scrip Asks...What Does 2023 Hold For Biopharma? Part 2: M&A And Partnering
Big Pharma Has Cash And Biotech Needs It
Deal-making between big pharma and biotech looks set to rise with a looming patent cliff increasing the need for the former to replenish its pipelines. Meanwhile, biotechs need partners to help them advance amid the ongoing big freeze on raising cash on public markets.
